Adjuvant treatment of melanoma.

Effectiveness of electrochemotherapy after IFN-α adjuvant therapy of melanoma patients. Radiol Oncol (2016) 0.77

Improved survival with ipilimumab in patients with metastatic melanoma. N Engl J Med (2010) 67.34

Improved survival with vemurafenib in melanoma with BRAF V600E mutation. N Engl J Med (2011) 45.46

Survival in BRAF V600-mutant advanced melanoma treated with vemurafenib. N Engl J Med (2012) 13.17

Improved survival with MEK inhibition in BRAF-mutated melanoma. N Engl J Med (2012) 11.72

Prognostic factors analysis of 17,600 melanoma patients: validation of the American Joint Committee on Cancer melanoma staging system. J Clin Oncol (2001) 10.20

High-dose interferon alfa-2b significantly prolongs relapse-free and overall survival compared with the GM2-KLH/QS-21 vaccine in patients with resected stage IIB-III melanoma: results of intergroup trial E1694/S9512/C509801. J Clin Oncol (2001) 4.84

Rate of growth in melanomas: characteristics and associations of rapidly growing melanomas. Arch Dermatol (2006) 4.51

Prognostic significance of autoimmunity during treatment of melanoma with interferon. N Engl J Med (2006) 4.47

Adjuvant therapy with pegylated interferon alfa-2b versus observation alone in resected stage III melanoma: final results of EORTC 18991, a randomised phase III trial. Lancet (2008) 3.62

Adjuvant interferon in high-risk melanoma: the AIM HIGH Study--United Kingdom Coordinating Committee on Cancer Research randomized study of adjuvant low-dose extended-duration interferon Alfa-2a in high-risk resected malignant melanoma. J Clin Oncol (2003) 3.13

Adjuvant immunotherapy of resected, intermediate-thickness, node-negative melanoma with an allogeneic tumor vaccine: impact of HLA class I antigen expression on outcome. J Clin Oncol (2002) 3.05

BEAM: a randomized phase II study evaluating the activity of bevacizumab in combination with carboplatin plus paclitaxel in patients with previously untreated advanced melanoma. J Clin Oncol (2011) 2.87

Randomized phase III study of 1 month versus 1 year of adjuvant high-dose interferon alfa-2b in patients with resected high-risk melanoma. J Clin Oncol (2009) 2.63

Resistance to BRAF inhibition in melanomas. N Engl J Med (2011) 2.58

Interferon alpha adjuvant therapy in patients with high-risk melanoma: a systematic review and meta-analysis. J Natl Cancer Inst (2010) 2.56

Phase I/II trial of tremelimumab in patients with metastatic melanoma. J Clin Oncol (2009) 2.53

Adjuvant therapy with pegylated interferon alfa-2b versus observation in resected stage III melanoma: a phase III randomized controlled trial of health-related quality of life and symptoms by the European Organisation for Research and Treatment of Cancer Melanoma Group. J Clin Oncol (2009) 2.50

Effect of long-term adjuvant therapy with interferon alpha-2a in patients with regional node metastases from cutaneous melanoma: a randomised trial. Lancet (2001) 2.40

Adjuvant therapy of stage III and IV malignant melanoma using granulocyte-macrophage colony-stimulating factor. J Clin Oncol (2000) 2.37

The prognostic value of circulating tumor cells in patients with melanoma: a systematic review and meta-analysis. Clin Cancer Res (2006) 2.36

Multivariate analysis of prognostic factors among 2,313 patients with stage III melanoma: comparison of nodal micrometastases versus macrometastases. J Clin Oncol (2010) 2.30

A pooled analysis of eastern cooperative oncology group and intergroup trials of adjuvant high-dose interferon for melanoma. Clin Cancer Res (2004) 2.28

Randomized trial of an allogeneic melanoma lysate vaccine with low-dose interferon Alfa-2b compared with high-dose interferon Alfa-2b for Resected stage III cutaneous melanoma. J Clin Oncol (2007) 2.19

Toward a molecular classification of melanoma. J Clin Oncol (2007) 1.95

Neoadjuvant treatment of regional stage IIIB melanoma with high-dose interferon alfa-2b induces objective tumor regression in association with modulation of tumor infiltrating host cellular immune responses. J Clin Oncol (2006) 1.83

Post-surgery adjuvant therapy with intermediate doses of interferon alfa 2b versus observation in patients with stage IIb/III melanoma (EORTC 18952): randomised controlled trial. Lancet (2005) 1.60

Impact of thorough block sampling in the histologic evaluation of melanomas. Arch Dermatol (2005) 1.50

Prospective, randomized, multicenter, double-blind placebo-controlled trial comparing adjuvant interferon alfa and isotretinoin with interferon alfa alone in stage IIA and IIB melanoma: European Cooperative Adjuvant Melanoma Treatment Study Group. J Clin Oncol (2005) 1.44

Systemic adjuvant therapy for patients with high-risk melanoma. Arch Dermatol (2007) 1.38

Psychiatric side effects of interferon therapy: prevalence, proposed mechanisms, and future directions. J Clin Oncol (2000) 1.32

Mechanisms and management of toxicities associated with high-dose interferon alfa-2b therapy. J Clin Oncol (2002) 1.28

Prognostic significance of serum S100B protein in high-risk surgically resected melanoma patients participating in Intergroup Trial ECOG 1694. J Clin Oncol (2008) 1.19

Utility of follow-up tests for detecting recurrent disease in patients with malignant melanomas. JAMA (1995) 1.15

Efficacy of low-dose interferon {alpha}2a 18 versus 60 months of treatment in patients with primary melanoma of >= 1.5 mm tumor thickness: results of a randomized phase III DeCOG trial. J Clin Oncol (2010) 1.14

PTEN expression in melanoma: relationship with patient survival, Bcl-2 expression, and proliferation. Clin Cancer Res (2005) 1.14

Biologic and prognostic significance of dermal Ki67 expression, mitoses, and tumorigenicity in thin invasive cutaneous melanoma. J Clin Oncol (2005) 1.11

Southwest Oncology Group S0008: a phase III trial of high-dose interferon Alfa-2b versus cisplatin, vinblastine, and dacarbazine, plus interleukin-2 and interferon in patients with high-risk melanoma--an intergroup study of cancer and leukemia Group B, Children's Oncology Group, Eastern Cooperative Oncology Group, and Southwest Oncology Group. J Clin Oncol (2014) 1.07

Quality-of-life-adjusted survival analysis of high-dose adjuvant interferon alpha-2b for high-risk melanoma patients using intergroup clinical trial data. J Clin Oncol (2002) 1.07

Cost effectiveness of adjuvant interferon in node-positive melanoma. J Clin Oncol (2007) 1.05

Serum YKL-40 predicts relapse-free and overall survival in patients with American Joint Committee on Cancer stage I and II melanoma. J Clin Oncol (2006) 1.04

Phase III trial comparing adjuvant treatment with pegylated interferon Alfa-2b versus observation: prognostic significance of autoantibodies--EORTC 18991. J Clin Oncol (2010) 1.00

Adjuvant low-dose interferon {alpha}2a with or without dacarbazine compared with surgery alone: a prospective-randomized phase III DeCOG trial in melanoma patients with regional lymph node metastasis. Ann Oncol (2008) 0.99

Immunologic mechanisms of antitumor activity. Semin Oncol (2002) 0.99

Anti-CTLA-4 antibody adjuvant therapy in melanoma. Semin Oncol (2010) 0.97

The interferon receptors. Semin Oncol (1997) 0.94

Adjuvant interferon alpha 2b in high risk melanoma - the Scottish study. Br J Cancer (2001) 0.93

Impact on survival by method of recurrence detection in stage I and II cutaneous melanoma. Ann Surg Oncol (1998) 0.87

Ultrasonography using simple diagnostic criteria vs palpation for the detection of regional lymph node metastases of melanoma. Arch Dermatol (2005) 0.83

Adjuvant therapy with pegylated interferon alfa-2b (36 months) versus low-dose interferon alfa-2b (18 months) in melanoma patients without macrometastatic nodes: an open-label, randomised, phase 3 European Association for Dermato-Oncology (EADO) study. Eur J Cancer (2012) 0.83

Relationship of the clinical response and binding of recombinant interferon alpha in patients with lymphoproliferative diseases. Blood (1986) 0.76